Curis, Inc. (NASDAQ:CRIS) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,276,538 shares, an increase of 39.6% from the October 31st total of 914,102 shares. Based on an average daily trading volume, of 325,109 shares, the days-to-cover ratio is currently 3.9 days. Currently, 4.7% of the company’s stock are sold short.
Several brokerages recently weighed in on CRIS. Zacks Investment Research downgraded Curis from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Cowen restated a “buy” rating on shares of Curis in a research note on Tuesday, September 25th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.33.
Shares of CRIS stock opened at $0.86 on Friday. Curis has a 1-year low of $0.81 and a 1-year high of $5.20. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 38.74. The firm has a market cap of $30.46 million, a P/E ratio of -0.48 and a beta of 1.16.
Institutional investors and hedge funds have recently modified their holdings of the business. LMR Partners LLP acquired a new stake in Curis during the 2nd quarter worth about $124,000. JPMorgan Chase & Co. lifted its position in Curis by 780.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 73,954 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 65,554 shares during the period. Paloma Partners Management Co acquired a new stake in Curis during the 2nd quarter worth about $223,000. Millennium Management LLC acquired a new stake in Curis during the 2nd quarter worth about $540,000. Finally, Renaissance Technologies LLC lifted its position in Curis by 30.7% during the 3rd quarter. Renaissance Technologies LLC now owns 620,729 shares of the biotechnology company’s stock worth $1,105,000 after acquiring an additional 145,809 shares during the period. 33.03% of the stock is owned by institutional investors.
Curis Company Profile
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
See Also: How Do I Invest in Dividend Stocks
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.